Filing Flows › Karyopharm Therapeutics (KPTI) › Q4 2024
Karyopharm Therapeutics (KPTI) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 19, 2025
Karyopharm Therapeutics (KPTI) reported revenue of $30.5M for the fourth quarter 2024 (Q4 2024), -9% from a year earlier and -21% from the quarter before. Operating margin was -102.4%, net loss $30.8M (100.8% of revenue).
Karyopharm Therapeutics, Q4 2024: revenue $30.5M (-10% year over year), operating margin -102.4%, net loss $30.8M, operating cash flow −$25.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.5M | -21% | -9% |
| Operating profit | −$31.3M | — | — |
| Net earnings | −$30.8M | — | — |
| Operating cash flow | −$25.8M | — | — |
What changed
Revenue was $30.5M in Q4 2024, down 9% year over year and down 21% from the previous quarter. Product was the largest line at 96% of revenue.
Operating costs exceeded revenue by $31.3M, an operating margin of -102.4%. Total costs fell 14% while revenue fell 9%. The quarter ended with a net loss of $30.8M, narrower than the previous quarter's $32.1M loss.
Operating cash flow was −$25.8M. Non-cash charges added back $81K of depreciation and $3.9M of share-based compensation. Capital expenditures of −$53K exceeded it, leaving free cash flow of −$25.8M.
Questions
What was Karyopharm Therapeutics' revenue in the fourth quarter 2024?
Karyopharm Therapeutics (KPTI) reported revenue of $30.5M for the fourth quarter 2024 (Q4 2024), -9% from a year earlier and -21% from the quarter before.
Was Karyopharm Therapeutics profitable in the fourth quarter 2024?
Operating loss was $31.3M (-102.4% of revenue) and net loss $30.8M.